JAK inhibitors — tofacitinib and upadacitinib — have received NMPA approval for ankylosing spondylitis, representing the first small-molecule oral disease-modifying options beyond NSAIDs for Chinese AS patients who cannot access or tolerate biologic therapy, with the China Sacroiliitis Treatment Market reflecting the emerging JAK inhibitor market position in China's...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek